Education
About Us
Working with TipRanks
Follow Us
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
RESEARCH TOOLSreports
KYTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.79 - $23.36
Previous CloseN/A
Volume87.17K
Average Volume (3M)297.73K
Market Cap
$89.02M
Enterprise Value-$116.11M
Total Cash (Recent Filing)$37.73M
Total Debt (Recent Filing)$10.56M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 20, 2025EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding43,214,916
10 Day Avg. Volume277,413
30 Day Avg. Volume297,725
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.07
Forecast
1Y Price Target
$15.25Price Target Upside640.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Kyverna Therapeutics, Inc. News
PremiumCompany Announcements
Kyverna Therapeutics Advances CAR T-Cell Therapy Trials---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressEnrollment in the Phase 2 KYSA-8 study for stiff person syndrome has progressed to 70%, marking significant advancement since earlier in the year.
Financial StabilityThe company ended the fourth quarter of 2024 with $286 million in cash, which is expected to fund operations into 2027, providing financial stability.
Regulatory MilestonesThe alignment with the FDA on the Phase 2 trial design for stiff person syndrome is a key milestone, indicating progress toward bringing KYV-101 to market.
Bears Say
Financial PerformanceKyverna reported a net loss of $0.87 per share, vs. a prior estimate of a net loss of $0.70 per share.
Operating ExpensesResearch and development, as well as sales, general, and administrative expenses, exceeded prior estimates.
Regulatory RisksThe broader development-stage biotech landscape has seen heightened regulatory risks stemming from the recent FDA shakeup.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.79 and its highest was $23.36 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $89.02M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is May 20, 2025 which is in 35 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Mar 27, 2025. The company reported -$0.868 earnings per share for the quarter, missing the consensus estimate of -$0.841 by -$0.027.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate is -1.12.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 43,214,916 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.868 in its last earnings report, missing expectations of -$0.841. Following the earnings report the stock price went down -15.254%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
---
Kyverna Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.25 (640.29% Upside)
$15.25 (640.29% Upside)
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.9%
Last 30 Days ▼ 4.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.37%
12-Months-Change
Fundamentals
Return on Equity
-80.74%
Trailing 12-Months
Asset Growth
307.63%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
---
KYTX Stock 12 Month Forecast
Average Price Target
$15.25
▲(640.29% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
C4 Therapeutics
―
Aziyo Biologics
―
Vor Biopharma
―
Climb Bio
―
Best Analysts Covering KYTX
1 Year
1 Year Success Rate
1/9 ratings generated profit
1 Year Average Return
-61.38%
reiterated a buy rating 18 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 11.11% of your transactions generating a profit, with an average return of -61.38% per trade.
---